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Abstract:  Objective: Investigation on anxiety, stress, depression, and quality of life (QoL) within STACCATO, a 
randomised trial of two treatment strategies: CD4 guided scheduled treatment interruption (STI) compared to continuous 
treatment (CT). 
Participants: Thai patients with HIV-infection enrolled in the STACCATO trial. 
Methods: Anxiety, depression assessed by the questionnaires Hospital Anxiety and Depression Scale (HADS) and DASS, 
stress assessed by the Depression Anxiety Stress Scale (DASS), and QoL evaluated by the HIV Medical Outcome Study 
(MOS-HIV) questionnaires. Answers to questionnaires were evaluated at 4 time-points: baseline, 24 weeks, 48 weeks and 
at the end of STACCATO. 
Results: A total of 251 patients answered the HADS/DASS and 241 answered the MOS-HIV of the 379 Thai patients 
enrolled into STACCATO (66.2 and 63.6% respectively). At baseline 16.3% and 7.2% of patients reported anxiety and 
depression using HADS scale. Using the DASS scale, 35.1% reported mild to moderate and 9.6% reported severe anxiety; 
8.8% reported mild to moderate and 2.0% reported severe depression; 42.6% reported mild to moderate and 4.8% reported 
severe stress. We showed a significant improvement of the MHS across time (p=0.001), but no difference between arms 
(p=0.17). The summarized physical health status score (PHS) did not change during the trial (p=0.15) nor between arm 
(p=0.45). There was no change of MHS or PHS in the STI arm, taking into account the number of STI cycle (p=0.30 and 
0.57) but MHS significant increased across time-points (p=0.007). 
Conclusion: Antiretroviral therapy improved mental health and QOL, irrespective of the treatment strategy. 
Keywords: HIV infection, mental health, quality of life, treatment interruption. 
INTRODUCTION 
  Combination antiretroviral therapy (cART) has changed 
HIV from a life threatening into a chronic condition. Anxiety 
and depression are common features of chronic diseases. 
Sixteen to 36% of patients with HIV infection have   
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underlying depression [1-3]. Since the advent of cART, few 
studies have focused on the prevalence of anxiety and 
depression. They remain common findings affecting the 
mental health, the quality of life (QoL), and response to 
cART [4]. Patients with less anxiety are, on average, more 
educated, employed, have a shorter duration of HIV disease, 
lower viral load, and more likely of female gender [5]. The 
perspective of never ending pill ingestion is dispiriting to 
many patients who feel imprisoned by their chronic disease 
[6-9]. Drug toxicity and especially lipodystrophy is another 
well recognized complication of cART that may affect 
quality of life of treated patients [10-13]. One strategy to The Impact of Combination Antiretroviral Therapy  The Open AIDS Journal, 2009, Volume 3    39 
deal with such problems was to reduce overall drug exposure 
by scheduled treatment interruptions (STI) but since the 
publication of the SMART trial’s results [14], this strategy is 
not viewed as an alternative care management anymore [15, 
16].  Treatment interruption with subsequent increases in 
viral load may increase anxiety and affect QoL through 
symptoms related to increased viremia. Nowadays STI are 
not recommended as an alternative to continuous 
antiretroviral therapy. Nevertheless the STACCATO trial 
substudy on mental disorders and QoL offers an important 
insight on the evolution of mental health and QOL with 
continuous and interrupted cART in a resource limited 
setting. 
METHODS 
The Swiss Thai Australia Treatment Interruption Trial 
(STACCATO) 
  STACCATO was a prospective, open-label, randomized, 
multicentre trial conducted in Thailand, Switzerland and 
Australia from January 2002 until November 2005 [17]. 
Patients with chronic HIV-1 infection who were naïve or 
antiretroviral-experienced and who presented a virological 
and immunological response to a pre-treatment phase of at 
least 3 months were recruited. Inclusion criteria were a CD4 
count above 350 cells/μL and HIV viral load (VL) <50 
copies/ml and no evidence for pre-existing drug resistance, 
such as detectable VL on prior antiretroviral therapy or 
history of virological failure. The patients were initially 
randomized in three groups: one group with continuous 
treatment (CT arm), one group with CD4 guided treatment 
interruptions (STI arm) with a CD4 threshold of 350 cells/L 
for interruption and re-initiation of antiretroviral therapy 
(STI:CT ratio 2:1). The third group had a week on therapy 
followed by a week off therapy. This group was stopped 
prematurely due to a high frequency of virological failure 
[18]. For the present study, only patients randomized in the 
CT and in the STI arms were analysed. 
Mental Health and QOL Scales 
  To assess mental health and QoL, we used standardized 
questionnaires which are validated in Thai language: HIV-
Medical Outcome Study (MOS-HIV) [19], Hospital Anxiety 
and Depression Scale (HADS) [20], Depression Anxiety 
Stress Scale (DASS) [21]. These test are not diagnostic tests 
but screening instruments and do not replace a assessment by 
a psychiatrist. Patients were asked to complete the validated 
Thai version of MOS-HIV, DASS and HADS questionnaires 
every 24 weeks beginning at baseline visit (randomisation). 
We will present patients’ answers at baseline, week 24, week 
48 and at the last visit before restarting cART (in the STI 
arm), named “last time-point visit” in the text. 
  The present study was performed in accordance with the 
approval of the ethical committee of the Thai Ministry of 
Public Health, and the local ethical committees. 
HIV Medical Outcome Study (MOS-HIV) 
  The MOS-HIV questionnaire measures health related 
QoL and was derived from the Medical Outcome Study   
 
designed to measure QoL in primary care and general patient 
populations [19, 22, 23]. It is divided in 10 subscores 
ranging from 0 to 100 (with better quality of the functional 
area when greater values) which assessed general health, 
physical functioning, role functioning, social functioning, 
cognitive functioning, pain, mental health, vitality, health 
distress, and QoL. In order to simplify data analysis and the 
interpretation of findings from clinical trials, and across 
studies, physical and mental health summary scores (PHS 
and MHS respectively) were calculated. For the PHS score, 
the physical function, pain, and role function scale scores 
contributed most strongly. For the MHS score, the mental 
health, health distress, quality of life, and cognitive function 
scales contributed most strongly. The vitality, general health 
and social functioning scales contributed to both factors. The 
summary scores were transformed to standardized z-scores, 
with a mean of 50 and a standard deviation of 10 [23]. MOS-
HIV has been translated in Thai and used in HIV studies in 
Thai patients [10, 24, 25]. According to several studies [26, 
27] the MOS-HIV questionnaire has good internal 
consistency, with a Cronbach alpha coefficient [28] reported 
exceeding 0.75. In the current study, the Cronbach alpha 
coefficient increased between baseline and the last time-
point visit going from 0.71 to 0.94 (0.39-0.64 for role 
functioning subscale), depending on the subscale studied. 
Hospital Anxiety and Depression Scale (HADS) 
  The HADS is a short self-assessment questionnaire 
developed specifically for an internal medicine context in 
which milder forms of anxiety and depression are more 
prevalent [29]. The HADS scale is divided in two sections: 
depression and anxiety. We considered patients to be 
depressed or anxious when they scored  11. Abnormal or 
borderline abnormal items were considered as “abnormal”. 
According to Savard et al. [30] the HADS has good internal 
consistency, with a Cronbach alpha coefficient [28] reported 
of 0.89. In the present study, we received only aggregated 
results which did not allow us to measure the Cronbach 
alpha coefficient in our study. 
Depression Anxiety Stress Scale (DASS) 
  The DASS is a 42 item self-report inventory that yields 3 
factors: depression, anxiety, and stress. This screening and 
outcome measure reflects the past 7 days, and reliability of 
the three scales has proven to be adequate [31]. Patients were 
considered to be depressed, anxious, or stressed when they 
answered at least one item with “mild” (score  10 for 
depression, score  8 for anxiety and score  15 for stress). 
According to Brown et al. [31] the DASS has an adequate 
internal consistency, with a Cronbach alpha coefficient [28] 
reported of 0.96, 0.89 and 0.93 for depression, anxiety and 
stress. In the present study, we received only aggregated 
results which did not allow us to measure the Cronbach 
alpha coefficient. 
  Both the DASS and HADS questionnaires are accepted 
tools to assess anxiety and depression [23]. The Thai version 
of both questionnaires has been validated for use in the Thai 
population. 
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Statistical Analysis 
  Both treatment arms were compared at baseline on 
demographic and clinical characteristics, HADS, DASS, 
mean PHS and mean MHS scores, using chi-square test of 
independence or Fisher’s exact test for categorical variables 
and Student-t tests or Mann-Whitney non-parametric test for 
continuous variables. Patients who filled out the initial 
questionnaire but not the last one were compared to those 
who filled out initial and final questionnaires on 
demographic and clinical characteristics and QoL scores. 
McNemar test was performed to assess the paired-proportion 
for abnormal score using HADS and DASS between baseline 
and last time-point visit. We considered abnormal scores as a 
combination of abnormal and borderline scores using HADS 
scale. For DASS, we stratified abnormal scores in mild to 
moderate and severe to extremely severe scores. 
  HADS, DASS and MOS scores were analyzed from 
baseline to last time-point visit. A mixed between-within 
subjects analysis of variance (ANOVA) was used to test the 
impact of the arm of randomization on PHS and MHS across 
four time points (0, 24, 48 weeks and last time-point visit). 
  All analyses were done with SPSS version 11.0 (SPSS 
Inc., Chicago, Illinois, USA). Two-sided p-value <0.05 was 
considered statistically significant. 
RESULTS 
  A total of 379 Thai patients were enrolled in 
STACCATO from January 2002, and 251 were included in 
the present substudy from March 2003. Among them, all 
patients had answered the HADS and DASS questionnaires 
at baseline, and 207 (82.5%) at the last time-point visit. For 
MOS-HIV, 241 (96%) patients answered the questionnaire at 
baseline and 133 patients at the last time-point visit (55.2%). 
  Baseline characteristics of patients who answered to 
HADS/DASS and MOS-HIV questionnaires are shown in 
Table 1. 
  Patients who only filled out the initial questionnaire on 
HADS and DASS (n=43, 17.1%) were compared to those 
who filled out both initial and final questionnaires (n=208). 
They were distributed equally in both treatment arms 
(p=0.46), had similar demographical characteristics (age 
p=0.86, sex p=0.99) and clinical characteristics (CDC stage 
p=0.69, proportion of MSM p=0.19, proportion of intra-
venous drug users p=0.82, proportion of heterosexual risks 
p=0.25, mean HIV-RNA before cART p=0.86, mean CD4 
count before cART p=0.57). Regarding distribution of 
anxiety, depression or stress from DASS scale, both groups 
had similar distributions (p=0.59, 0.99 and 0.68 respectively) 
at baseline. Distribution of depression and anxiety using 
HADS scale at baseline were also similar between both 
groups (p=0.99 and 0.13 respectively). 
  Patients who filled out the initial questionnaire on MOS-
HIV (n=51, 21.2%) were compared to those who filled out 
both initial and final questionnaires (n=190). They were 
distributed equally in both treatment arms (p=0.43), had 
similar demographical characteristics (age p=0.59, sex 
Table 1.  Baseline Characteristics of Patients Assessed with DASS/HADS and MOS-HIV Questionnaires 
 
HADS / DASS (N=251)  MOS-HIV (N=241) 
  CT Arm 
N=76 
STI Arm 
N=175  p-Value  CT Arm 
N=82 
STI Arm 
N=159  p-Value 
Male gender (%)  25 (32.9)  77 (44.0)  0.10  50 (61.0)  79 (49.7)  0.10 
Route of HIV infection (%) 
Heterosexual 
MSM 
IVDU 
 
67 (88.2) 
7 (9.2) 
1 (1.3) 
 
154 (88.0) 
18 (10.3) 
0 
0.33 
 
 
72 (87.8) 
9 (11.0) 
1 (1.2) 
 
131 (82.4) 
25 (15.7) 
0 
0.56 
 
Naïve patient (%)  52 (68.4)  115 (65.7)  0.63  50 (61.0)  93 (58.5)  0.71 
Mean duration of HIV, months (±SD)  31.9 (±24.1)  33.1 (±28.6)  0.76**  30.2 (±20.9)  35.4 (±30.1)  0.66** 
Age, years (±SD)  35.5 (±8.1)  35.4 (±8.0)  0.91*  36.6 (±7.6)  35.3 (±7.7)  0.22* 
CD4 count, cells/mm3 (±SD)  254 (±113)  265 (±88)  0.46**  491 (±120)  491 (±150)  0.98* 
Viral load, log10 cp/mL (±SD)  4.7 (±0.7)  4.68 (±0.7)  0.88**  4.7 (±0.7)  4.7 (±0.6)  0.90 
Number of STI cycles (%) 
1 
2 
>=3 
-   
72 (41.1) 
65 (37.1) 
38 (21.7) 
   
62 (39.0) 
51 (32.1) 
46 (28.9) 
 
N° who answered questionnaire (%) 
Baseline 
Week 24 
Week 48 
Last time-point visit 
 
76 (100) 
60 (78.9) 
53 (69.7) 
65 (85.5) 
 
175 (100) 
145 (82.9) 
111 (63.4) 
142 (81.1) 
 
- 
0.46 
0.33 
0.40 
 
82 (100) 
69 (84.1) 
60 (73.2) 
46 (56.1) 
 
159 (100) 
129 (81.1) 
120 (75.5) 
87 (54.7) 
 
- 
0.56 
0.70 
0.84 
Mean participation, months (±SD)  14.5 (±5.6)  14.4 (±5.9)  0.91**  18.1 (±7.5)  16.9 (±6.9)  0.21 
* Mann-Whitney test because equality of variance not assumed. ** Student-t test. The Impact of Combination Antiretroviral Therapy  The Open AIDS Journal, 2009, Volume 3    41 
p=0.16) and clinical characteristics (CDC stage p=0.90, 
proportion of MSM tends to higher among patients who 
filled both periods p=0.06, proportion of intra-venous drug 
users p=0.99, proportion of heterosexual risks p=0.19, mean 
HIV-RNA before cART p=0.24, mean CD4 count before 
cART p=0.53). Regarding mean PHS and MHS scores at 
baseline, there was no significant difference (p=0.27 and 
0.72 respectively). 
 Table  2 presents the prevalence of anxiety or depression 
using HADS and the prevalence of mild-moderate and 
severe to extremely severe anxiety, depression and stress 
using DASS in each arm, at baseline; there is no difference 
between arms (all p-value>0.05). We show that 2.6% of 
patients randomized in the CT arm and 0.6% in the STI arm 
had a combination of anxiety and depression at baseline with 
the HADS scale (p=0.22). With the DASS scale, 3.9% of 
patients included in the CT arm and 1.2% of patients 
included in the STI arm had a combination of mild to 
moderate anxiety and depression (p=0.16); 2.6% of patients 
randomized in the CT arm versus none in the STI arm had a 
combination of severe anxiety and depression at baseline 
(p=0.09). 
 Table  3 shows the comparison between arms of anxiety, 
depression and stress from baseline to last time-point visit 
(65 patients in the CT arm and 142 in the STI arm). We 
found a significantly lower proportion of mild to moderate 
stress between both time-points in the STI arm (p=0.004) 
and a significantly lower proportion of severe to extremely 
severe anxiety between both time-points in the STI arm 
(p=0.008). The comparison of abnormal values regarding 
anxiety, depression and stress between baseline and last 
time-point visit was similar inside CT arm whatever HADS 
or DASS scales; nonetheless there was a tendency for higher 
severe stress in the CT arm at last time-point visit compared 
to baseline (p=0.07). We found a significant higher 
proportion of depression at last time-point visit compared to 
baseline in the STI arm using the HADS scale (McNemar 
test, p=0.004) while the difference was not statistically 
different using DASS scale. With the HADS, we found that 
anxiety was the same between baseline and last time-point 
visit in the STI arm while with the DASS, the proportion of 
severe anxiety was significantly decreased in the STI arm at 
last time-point visit (p=0.008) but not for mild to moderate 
anxiety (p=0.75). Regarding stress, the proportion of patients 
who were mildly to moderately stressed at baseline 
decreased significantly at last time-point visit in the STI arm 
(p=0.04) but the proportion of severely stressed patients was 
similar between both time-points within the STI arm 
(p=0.32). 
  In the MOS-HIV questionnaire exploring the QoL at 
baseline, the mean MHS score was significantly lower in the 
STI arm compared to CT arm (49.1±8.3 versus 51.7±7.6, 
p=0.02) and the PHS score was similar between arms 
(54.4±6.3 versus 53.8±6.6, p=0.53). The variation of the 
PHS and MHS scores from baseline to last time-point visit 
(with their 95% confidence interval) is presented in Fig. (1). 
Regarding the PHS, mixed between-within subjects ANOVA 
showed that there was no significant interaction between the 
four time-points and the randomization arm (p=0.74; partial 
eta squared =0.01). There was neither change of PHS across 
the four time-points (p=0.15) nor between the two arms of 
randomization (p=0.45) (Fig. 1b). Regarding the MHS, we 
Table 2.  Proportion of Anxiety, Depression and Stress Using HADS and DASS Scales between CT and STI Arms at Baseline 
 
CT Arm 
(N=76) 
STI Arm 
(N=175) 
 
N  %  N  % 
p-Value 
HADS scale          
Anxiety   12  15.8  29  16.6  0.88 
Depression   8  10.5  10  5.7  0.17 
Combination of anxiety and depression  2  2.6  1  0.6  0.22* 
DASS scale          
Anxiety 
Mild-moderate 
Severe-extremely severe 
 
25 
5 
 
32.9 
6.6 
 
63 
19 
 
36.0 
10.6 
 
0.64 
0.29 
Depression 
Mild-moderate 
Severe-extremely severe 
 
7 
3 
 
9.2 
3.9 
 
15 
2 
 
8.6 
1.1 
 
0.87 
0.16 
Combination of anxiety and depression 
Mild-moderate 
Severe-extremely severe 
 
3 
2 
 
3.9 
2.6 
 
2 
- 
 
1.2 
- 
 
0.16* 
0.09* 
Stress 
Mild-moderate 
Severe-extremely severe 
 
33 
4 
 
43.4 
5.3 
 
74 
8 
 
42.3 
4.6 
 
0.87 
0.76* 
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showed that there was no significant interaction between the 
four time-points and the randomization arm (p=0.43). There 
was a substantial main effect across time-points (p=0.001, 
partial eta squared = 0.128 corresponding to a moderate to 
high effect size) showing an increase of mental health across 
the 4 time-points. The main effect comparing the 
randomization arm was not significant (p=0.17, partial eta 
squared = 0.014), suggesting no difference in the evaluation 
of mental health between both randomization arms (Fig. 1a). 
When we restricted our analysis to STI arm taking into 
account the number of STI cycles (divided in three 
categories: 1, 2 or  3 STI cycles), mixed between-within 
subjects ANOVA assessing physical health showed that 
there was no significant interaction between the four time-
points and the number of STI cycles (p=0.71), PHS was 
stable across the four time-points (p=0.64) and there was no 
significant change regarding the number of STI cycles 
(p=0.27). The model that assessed mental health showed that 
there was no significant interaction between time and the 
number of STI cycles (p=0.57) but that there was a 
significant increase of MHS across the four time-points 
(p=0.007) without a difference regarding the number of STI 
cycles (p=0.30). 
  We used a multivariate linear model to explore the 
association between PHS and MHS scores at baseline and 
final visit with various covariates. At baseline, MHS was 
greater among patients over 44 years (p=0.08), among 
patients infected through heterosexual intercourse (p=0.8), 
when CD4 count was above 500 cells/ L (p=0.009) and 
increased with weight (p=0.09). PHS at baseline was lower 
among patients infected through heterosexual intercourse 
(p=0.04) and among patients screened for HIV for more than 
6 months (p=0.12). For the last visit, MHS was lower among 
patients infected through heterosexual intercourse (p=0.01), 
among patients randomized in the CD4 guided group 
(p=0.04) and among patients who lost more than 5 kg from 
baseline (p=0.001). For PHS, the score was lower in women 
(p=0.06), if patients had triglycerides above 200 mg/dl 
(p=0.05), if LDL-cholesterol was greater than 140 mg/dl 
(p=0.09) and if patients lost more than 5 kg from baseline 
(p=0.06). Globally, multivariate linear models did not fit 
perfectly with adjusted covariates (R
2<0.10 for the 4 
models). 
DISCUSSION 
  Since the advent of cART, morbidity and mortality of 
HIV-infections have drastically decreased in industrialized 
countries [32]. HIV infection has become a chronic disease 
with a quasi normal life expectancy. In the cART era, QoL 
now represents a challenge in the care management of HIV-
infected patients. Stigmatizing side effects such as 
lipodystrophy [33] have to be taken into account choosing 
antiretroviral drugs. The strategy of STI was proposed as an 
alternative to continuous cART in patients with moderate 
immunosuppression (CD4 count above 350 cells/μL) but 
since the publication of the SMART trial’s results, it is not 
recommended at a patient-population level [14]. Indeed with 
few exceptions [34, 35], the results of STI on QoL were 
disappointing [36-38]. In some studies its impact on general 
health perception was even negative [14, 39]. In accordance, 
our results showed no benefit of STI on mental health and 
QoL. But what appeared is that cART by itself has a positive 
effect on mental health. Even in patients randomized to the 
STI arm, and who for unknown reasons had MHS scores 
which were significantly lower at baseline, a significant 
increase of MHS scores across study time-points was seen. 
This suggests that they have corrected their MHS score 
during STACCATO trial while on continuous treatment. At 
last time-point visit they reached the same scores as patients 
randomized in the CT arm at baseline. We also showed a 
tendency to lower proportions of anxiety and stress between 
baseline and last time-point visit among patients randomized 
Table 3.  Comparison of Depression, Anxiety and Stress Prevalence between Baseline and Last Time-Point Visit Scored by HADS 
or DASS between Both Randomization Arms 
 
Anxiety  Depression  Stress  Arms 
CT 
(n=65) 
STI 
(n=142) 
CT 
(n=65) 
STI 
(n=142) 
CT 
(n=65) 
STI 
(n=142) 
HADS scale (%) 
Abnormal values* 
Baseline 
Last time-point visit 
p-value 
 
 
12 (18.5) 
13 (20.0) 
0.99 
 
 
23 (16.2) 
28 (19.7) 
0.49 
 
 
8 (12.3) 
8 (12.3) 
0.99 
 
 
6 (4.2) 
18 (12.7) 
0.004 
 
 
- 
- 
- 
 
 
- 
- 
- 
DASS scale (%) 
Mild to moderate 
Baseline 
Last time-point visit 
p-value 
Severe to extremely severe 
Baseline 
Last time-point visit 
p-value 
 
 
22 (33.8) 
20 (30.8) 
0.67 
 
5 (7.7) 
2 (3.1) 
0.26 
 
 
48 (33.8) 
46 (32.4) 
0.75 
 
15 (10.6) 
5 (3.5) 
0.008 
 
 
7 (10.8) 
5 (7.7) 
0.53 
 
1 (1.5) 
0 
0.32 
 
 
9 (6.3) 
8 (5.6) 
0.78 
 
1 (0.7) 
0 
0.32 
 
 
20 (30.8) 
12 (18.5) 
0.07 
 
2 (3.1) 
4 (6.2) 
0.32 
 
 
42 (29.6) 
29 (20.4) 
0.04 
 
3 (2.1) 
5 (3.5) 
0.32 
* Borderline and abnormal items were considered abnormal. Numbers of patients changed depending on the subscale. The Impact of Combination Antiretroviral Therapy  The Open AIDS Journal, 2009, Volume 3    43 
in the STI arm. Regarding depression, we found 
contradictory results. A higher rate of depression at the last 
time-point visit compared to baseline among patients 
randomized in the STI arm, but not in the continuous arm. 
  For our investigation we used the well-known and 
validated questionnaires HADS, DASS and MOS-HIV. 
MOS-HIV also measures fatigue, a important variable 
affecting QOL in HIV-HCV co-infection [40]. These 
questionnaires are in fact measurement tools that have 
coefficients of variation comparable to CD4 counts [41, 42]. 
We showed that the number of patients who answered the 
questionnaires was different and we explained this disparity 
by the fact that in Thailand the STACCATO trial was 
organized in seven centres with at least seven clinical 
investigators who did not always adhere to the protocol. The 
focus was on mental health, anxiety, stress and depression in 
particular. Most of our patients lived in the Bangkok 
metropolitan area with a lifetime prevalence of anxiety 
(a) 
 
(b) 
 
Fig. (1). Line graphs of mean scores with their 95% confidence intervals for the Mental Health summary (MHS) (1a) and Physical Health 
Summary (PHS) (1b) by arm and across the four time-points. MHS and PHS are T-scored with a mean of 50 and a standard deviation of 10. 
Last visit corresponds to last time-point visit. 44    The Open AIDS Journal, 2009, Volume 3  Nüesch et al. 
disorders in the general population of 10.2%, and 19.9% 
depression [43]. In the literature prevalence of depression 
and anxiety among people living with HIV-infection and 
treated with antiretroviral therapy varies from 4% to 51% 
[44-49]. This wide range is due to the multiplicity of settings 
evaluated, questionnaires used and to the diversity of mental 
disorders studied, from mild to severe. In our study 
prevalence of severe depression measured at baseline by 
DASS was 2.0%, which is low. If mild and moderate forms 
are included, depressive symptoms were seen in 8.8% and 
anxiety in 35.1%. Mental health and QoL were found similar 
in the STI arm compared with CT. The number of STI did 
not modify the results at the different questionnaires as we 
could expect. 
  We should address some limitations to our study. First 
only 63.6-66.2% of all enrolled Thai patients answered the 
MOS-HIV and HADS/DASS questionnaires, which is few. 
To rule out biases, we compared patients who only filled out 
the initial questionnaire on HADS and DASS to those who 
filled out both initial and final questionnaires. They were 
distributed equally within both arms and had similar 
characteristics making a selection unlikely. We should admit 
a potential selection bias because all participants were 
volunteers. This could explain the relatively low prevalence 
of anxiety, depression or stress at baseline. Probably they are 
not representative of the entire HIV-infected population in 
whom mental disorders are more frequent [1-3]. Also it must 
be emphasized that the screening tests we used are not 
equivalent to an assessment by a psychiatrist. Finally time 
within randomized phase of STACCATO was between 14.4 
and 16.5 months and most of the patients had less than 2 
treatment interruptions which could also explained the 
relatively low prevalence of mental health disorders 
emerging during the study. But even in this motivated group 
the positive effect of cART was evident. 
  In a previous publication, we showed that CD4 guided 
STI led to less drug toxicity, particularly neuropathy, but 
also to more HIV-associated symptoms like oral candidiasis 
or acute retroviral syndrome [17]. Most of the drug toxicity 
was associated with stavudine, a drug still widely used in 
resource limited settings. Even with this relatively toxic 
regimen, QoL improved with continuous cART, not with 
STI. Further, HIV infection is known to affect the central 
nervous system [50]. Thus uncontrolled viremia can have an 
impact on mental health. The vast majority of our patients 
started antiretroviral therapy approximately 6 months before 
enrollment into STACCATO. This relatively short duration 
of treatment must be taken into account when interpreting 
our findings, as treatment fatigue might be less pronounced 
than in other trials with longer duration of cART. On the 
other hand, trials with a longer previous time on cART failed 
to show a benefit of STI on QoL as well [14, 36-39]. 
  In summary, continuous cART has a beneficial effect on 
mental health in Thai patients with chronic HIV infection. 
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